Anzeige
Mehr »
Login
Montag, 27.09.2021 Börsentäglich über 12.000 News von 673 internationalen Medien
Breaking News: TAAT Global verdoppelt die Anzahl der Shops auf 1.000!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrFacing class action lawsuit over insulin pricing, Novo Nordisk inks $100M settlement with disgruntled investors
FrGilead, Merck and others slapped with 'pay-for-delay' lawsuits over lucrative HIV and cholesterol meds
FrFDA's ongoing review of accelerated cancer approvals targets 2 drugs from Secura and Aurobindo
FrResponding to global vaccine demand, Cytiva pledges $52.5 million to build South Korean factory
FrMerck will pay royalties on next-gen pneumococcal shot to settle Pfizer patent fight
FrRegeneron and Roche's COVID drug wins WHO backing, but agency calls for lower prices and better access
FrAstraZeneca, Merck target broad use of Lynparza in prostate cancer as PARP rivals Pfizer, J&J, Clovis loom
FrFierce Pharma Asia-Enhertu's big win; Biogen-Samsung's Lucentis biosimilar; Clover's COVID vaccine data
DoCDMO Lonza strikes deal with Allarity Therapeutics to manufacture cancer drug candidate dovitinib
DoTakeda breached its contract with AbbVie by failing to supply prostate cancer drug Lupron, court rules
DoFaced with generic rivals, Amarin cuts 400-plus sales reps as part of revamped Vascepa strategy
DoVaccine players in Argentina, Brazil selected as regional producers for COVID-19 shots
DoAmid heated debate, FDA hands limited nod to Pfizer for COVID-19 vaccine boosters
DoOn a JAK roll, Incyte wins FDA green light to expand Jakafi in chronic graft-versus-host disease
DoPfizer CEO Bourla asks employees to join the scrum for D.C. drug-pricing fight
DoTakeda breaks ground on $14M green building at Singapore manufacturing plant
DoDo not enter: Biogen reps banned from D.C.-area neurology clinics over controversial Alzheimer's drug Aduhelm
DoSmall but formidable activist investor Bluebell takes stake in GlaxoSmithKline, asks CEO Walmsley to reapply for job: FT
MiReckitt's Mucinex ushers in cold and flu season with tribute to Latinos making a difference
MiLonza's march of manufacturing expansion continues with more backyard plans
MiPlay-by-play: How Sanofi jacked up its offer twice to seal the $1.9B deal for Kadmon
MiWith $68.2M investment from India's Serum, Oxford Biomedica set to add capacity and 120 jobs at its 'Oxbox' site
MiNovartis reshuffling doesn't portend a pullback from gene therapy, company says
MiStruggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm: analyst
MiPfizer, Moderna, AstraZeneca and other COVID vaccine companies face urgent calls to ramp up access around the world